MGMT METHYLATION
TESTING IN GBM
MGMT promoter methylation predicts which GBM patients will benefit most from temozolomide chemotherapy β and which elderly patients may be better served by radiation alone. It is the most clinically actionable biomarker in GBM, and its testing must precede treatment decisions.
analyticsAt a Glance
- check_circleMGMT methylation is present in 40β45% of GBM β the single most favourable prognostic factor in IDH-wildtype disease
- check_circleMGMT-methylated GBM: median OS 18β22 months with Stupp protocol; MGMT-unmethylated: 12β14 months
- check_circleIn elderly patients (>65β70), MGMT methylation determines whether temozolomide alone, RT alone, or combined TMZ + RT is most appropriate
- check_circleMGMT testing by pyrosequencing is the reference standard β IHC is not reliable and should not be used for clinical decisions
What Is MGMT and Why Does Its Methylation Matter in GBM?
O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that removes alkyl groups from O6 position of guanine β the exact DNA adduct that temozolomide (TMZ) and other alkylating chemotherapy agents create to induce tumour cell death. When MGMT is active, it repairs TMZ-induced DNA damage β neutralising the drug's cytotoxic effect. When the MGMT gene promoter is methylated (epigenetically silenced), MGMT enzyme is absent β TMZ-induced DNA damage goes unrepaired and tumour cells die.
βMGMT methylation is the molecular explanation for why some GBM patients respond remarkably well to temozolomide while others show essentially no benefit. Knowing the MGMT status before treatment allows the treatment to be aligned with the tumour's known biology β rather than giving all patients the same chemotherapy regardless of predicted response.β
MGMT-Methylated GBM: What It Means Clinically
The MGMT promoter is silenced by CpG island methylation β MGMT enzyme is not produced in the tumour cells. When temozolomide alkylates DNA, the adducts accumulate and trigger apoptosis. These patients respond better to the Stupp protocol, have longer progression-free survival, and achieve median overall survival of 18β22 months vs 12β14 months in unmethylated patients. The 5-year survival rate in MGMT-methylated GBM (with standard treatment) reaches approximately 15β20%.
MGMT-Unmethylated GBM: Implications and Alternatives
Active MGMT enzyme repairs TMZ-induced DNA damage β the tumour is relatively resistant to alkylating chemotherapy. These patients gain limited benefit from TMZ but still receive it in the Stupp protocol because the benefit is not zero. For elderly MGMT-unmethylated patients, evidence suggests TMZ alone provides little benefit β radiation alone or participation in clinical trials targeting alternative pathways is appropriate. Novel combinations (lomustine, bevacizumab, immunotherapy) are under investigation specifically for this subgroup.
MGMT Methylation and Survival: The Evidence
Published data from the Stupp trial and subsequent MGMT-stratified analyses establish the survival benefit associated with MGMT methylation.
MGMT Methylation and Survival β Stupp Trial (NEJM 2005) MGMT Analysis
Source: Hegi et al., NEJM 2005;352:997β1003. RT + TMZ vs RT alone; results stratified by MGMT methylation status.
- Median OS: MGMT-methylated, RT + TMZ21.7 mo
- Median OS: MGMT-methylated, RT alone15.3 mo
- Median OS: MGMT-unmethylated, RT + TMZ12.7 mo
- Median OS: MGMT-unmethylated, RT alone11.8 mo
MGMT Methylation in Elderly GBM β NOA-08 Trial and Nordic Trial
MGMT-methylated elderly patients benefit most from TMZ; unmethylated patients benefit more from RT alone. Critical for elderly GBM treatment decisions.
- Elderly MGMT-methylated: OS with TMZ alone8.4 mo
- Elderly MGMT-methylated: OS with RT alone4.6 mo
- Elderly MGMT-unmethylated: OS with RT alone9.4 mo
- Elderly MGMT-unmethylated: OS with TMZ alone6.0 mo
How MGMT Methylation Is Tested: Methods, Accuracy, and What to Request
MGMT testing methodology is a critical quality issue β the wrong method produces unreliable results that may guide treatment incorrectly.
| Method | Technique | Accuracy | Recommended? | Notes |
|---|---|---|---|---|
| Pyrosequencing | Quantitative bisulfite sequencing of CpG sites in MGMT promoter (typically sites 76β80 or 84β90) | Gold standard β quantitative, reproducible, clinically validated | YES β reference standard | Methylation >8β10% is typically 'methylated'; threshold varies by laboratory protocol |
| MSP (Methylation-Specific PCR) | PCR using methylation-specific and unmethylation-specific primers | Semi-quantitative; widely available; validated in multiple trials | YES β acceptable | Used in EORTC/NCIC trials; technically demanding; results can vary between labs |
| Bisulfite pyrosequencing (extended) | Extended panel of CpG sites beyond the minimal region | More reproducible for borderline cases | YES β preferred at specialist centres | Recommended for equivocal results or research settings |
| IHC (Immunohistochemistry) | Anti-MGMT antibody on tissue sections | Poor β does not reliably reflect MGMT promoter methylation status | NO β not recommended | IHC staining does not correlate with gene methylation; multiple studies show poor concordance with pyrosequencing; should NOT be used for clinical MGMT decisions |
| EPIC Array / Methylation array | Genome-wide DNA methylation profiling (450K/EPIC BeadChip) | Highest accuracy; provides MGMT plus full methylation profile + CNS tumour classifier | YES β where available | Most comprehensive molecular profiling; increasingly used at reference neuropathology centres; MGMT derived from array data is highly reliable |
How MGMT Methylation Status Changes Treatment Decisions
MGMT status influences specific treatment decisions at different stages of the GBM care pathway.
MGMT-Methylated GBM
- Full Stupp protocol strongly indicatedTemozolomide (concurrent + adjuvant) provides significant survival benefit β MGMT-methylated patients should always receive the full chemoradiation protocol unless contraindicated by performance status or age.
- Adjuvant lomustine + TMZ combination (in selected high-risk cases)The CATNON/CeTeG trials showed that lomustine + temozolomide combination may further improve outcomes in MGMT-methylated recurrent and newly diagnosed GBM at selected centres.
- Better candidate for standard maintenance TMZSix cycles of adjuvant TMZ after concurrent chemoradiation provides clear benefit in MGMT-methylated disease β adherence to the full maintenance course is particularly important.
- Better overall prognosis β realistic survival discussionMedian OS 18β22 months with standard treatment; 5-year survival ~15β20% β a meaningfully different prognosis conversation from MGMT-unmethylated disease.
MGMT-Unmethylated GBM
- TMZ still used but benefit is limitedMGMT-unmethylated patients receive TMZ in the Stupp protocol as benefit is not zero β but the survival advantage over radiation alone is small (12.7 vs 11.8 months).
- Elderly MGMT-unmethylated: RT alone may be superiorNOA-08 and Nordic trial data show elderly MGMT-unmethylated patients survive longer with radiation alone than with TMZ alone β do not use TMZ-only regimens in this subgroup.
- Priority candidate for clinical trialsMGMT-unmethylated patients gain least from standard TMZ β they are the highest-priority population for alternative strategies: immunotherapy, TTFields, targeted agents, and investigational combinations.
- Discuss realistic prognosis openlyMedian OS 12β14 months with standard treatment β advanced care planning and goals-of-care conversations are particularly important in MGMT-unmethylated GBM.
MGMT Methylation: Key Clinical Numbers
Reference figures for clinical practice and patient counselling.
- 40β45%Of IDH-wildtype GBM are MGMT-methylatedThe most important minority in GBM β this subgroup drives most of the long-term survivors in GBM cohorts.
- 21.7 moMedian OS: MGMT-methylated GBM treated with RT + TMZ (Hegi 2005)The pivotal Hegi analysis of the Stupp trial β establishing the MGMT methylation biomarker as the dominant prognostic factor in GBM.
- IHC β IHC does not reliably reflect MGMT methylation β do NOT useMGMT IHC staining is a common pitfall β it does not correlate with gene methylation and should never be used for clinical MGMT decision-making.
- >8β10%Methylation percentage threshold for 'MGMT-methylated' by pyrosequencingLaboratory-specific thresholds vary (8β20% methylation is typically positive) β always review the laboratory's reference range when interpreting results.
More from the Glioblastoma Resource Library
Continue exploring GBM molecular markers and treatment protocols.
- β Glioblastoma β Complete Guide
- What Is Glioblastoma (GBM)? Understanding the Most Aggressive Brain Tumour
- IDH Mutation in Brain Tumours: What It Means and Why It Matters
- The Stupp Protocol: Surgery, Radiation, and Temozolomide for GBM
- Tumour Treating Fields (TTFields/Optune): How It Works
- GBM at Recurrence: Treatment Options After First Progression
Frequently Asked Questions
Common questions about MGMT methylation testing and its treatment implications.
About MGMT Testing
My pathology report lists MGMT status as 'positive' β does this mean the tumour is methylated?
This is a critically important terminological issue that confuses many patients. In MGMT reporting, the convention varies between laboratories: some report 'MGMT methylated' (favourable β TMZ-sensitive), which may be described as 'MGMT positive' (meaning the methylation is positive). Others report 'MGMT protein positive' (by IHC) β which means the enzyme is present and active, which is the unfavourable finding (TMZ-resistant). The two usages of 'positive' mean the opposite thing. Always ask your neuropathologist or oncologist to clarify in plain language: 'Is the MGMT promoter methylated, meaning the MGMT enzyme is silenced and the tumour is expected to respond well to temozolomide?' If the answer is yes to methylation β your prognosis is better. If the report used IHC rather than pyrosequencing, request the test to be repeated with the correct methodology.
My GBM is MGMT-unmethylated β are there any effective treatments?
Yes β MGMT-unmethylated GBM is not untreatable. Standard chemoradiation is still given (Stupp protocol), though the benefit from the temozolomide component is smaller. Tumour treating fields (TTFields/Optune) provide additional survival benefit independent of MGMT status β the EF-14 trial showed TTFields benefit in both MGMT-methylated and unmethylated subgroups. For recurrence, lomustine, bevacizumab, and participation in clinical trials are the main options. MGMT-unmethylated GBM is the population with the strongest rationale for clinical trial participation β immunotherapy (checkpoint inhibitors, CAR-T, vaccine approaches) and targeted agents are being evaluated specifically in this population. CancerFax can advise on which clinical trials are open at Chinese and Indian centres for MGMT-unmethylated recurrent GBM.
My father is 74 with newly diagnosed GBM β should he receive temozolomide given his age?
MGMT methylation status is the decisive factor for elderly GBM patients. The NOA-08 and Nordic trials compared TMZ alone vs radiation alone (not combined chemoradiation) in elderly patients: MGMT-methylated elderly patients lived longer with TMZ alone than RT alone; MGMT-unmethylated elderly patients lived longer with RT alone than TMZ alone. For MGMT-methylated elderly patients, TMZ (with or without abbreviated RT) is appropriate. For MGMT-unmethylated elderly patients, RT alone (hypofractionated schedule, 40 Gy in 15 fractions) is the preferred approach β adding TMZ provides minimal benefit while adding toxicity that reduces quality of life in a frail patient. This is why MGMT testing before treatment is particularly important in elderly GBM β it directly determines whether chemotherapy should be given at all.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Has Your GBM Been Tested for MGMT Methylation?
CancerFax can arrange specialist review of your GBM pathology to confirm whether MGMT methylation testing was performed and interpreted correctly β and advise on how your result should influence your treatment plan.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.